Active ingredientCerdulatinibCat. No. P-C114-001CAS 1198300-79-6Family · Pharmaceutical analytical standards
Cerdulatinib
An experimental oral dual-target inhibitor that blocks both the SYK kinase and the JAK kinases: it has been studied for blood cancers and in 2018 received US orphan drug designation for peripheral T-cell lymphoma. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?More than dual, it is almost a 'multi-tool': it hits as many as six different kinases with nanomolar potency, namely SYK, TYK2, JAK1, JAK2, JAK3 and FMS.
Go to the active ingredient →Active ingredientCerdulatinibCat. No. P-C114-001CAS 1198300-79-6
Isotopically labelledCerdulatinib-d8Cat. No. P-C114-002
NitrosamineN-Nitroso CerdulatinibCat. No. P-C114-003
ImpurityCerdulatinib Impurity 1Cat. No. P-C114-004
ImpurityCerdulatinib Impurity 2Cat. No. P-C114-005
ImpurityVexicitinibCat. No. P-C114-006CAS 2230362-69-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.